Fellow weedstock degenerates, I've been deep in the CSE: $HERB OTCQB: $LUFFF filings and press releases the last couple months and holy shit — this company is executing like a rocket ship on all cylinders. E-commerce platform + house of brands + medical insurance tailwinds + international exports. Here's the bullet-proof bull case based on fresh Q1/Q2 2026 momentum:

• Veterans' channel is straight-up exploding (high-margin, recurring revenue machine): Veteran registrations up ~400% in Q1 2026 alone vs. all of 2025. Insured gross sales for the entire year of 2025 were $675k... they basically matched that in the first FOUR MONTHS of 2026, putting them on a ~$2.23M annualized run rate already (with Q2 estimates pushing toward $3.5M–$4M). Each vet client averages ~$7k/year in insured spend at 50%+ gross margins. Just launched the upgraded HeroDispatch.com e-comm platform in early May targeting the massive $245M+ insured medical segment — concierge insurance billing, zero out-of-pocket for vets via Blue Cross/VAC. Retention >89% and they're just getting started scaling the marketing. This is sticky, government-backed revenue that prints cash.
• Exports are hitting escape velocity (first major gummy shipment already banked): April 30 they completed their first international gummy export to Australia — $350k revenue in ONE shipment. More follow-on orders expected throughout 2026. They're already shipping medical flower to Germany (298kg via EU-GMP partner in Portugal) and actively lining up new markets. This is high-margin B2B international growth on top of their domestic base, and with cannabis rescheduling momentum in the US they're positioning hard for future North American upside too. Triple export volumes by 2028? They're already delivering.
• Recreational sales through the Canadian market are about to rip (new brand just dropped): May 12 they launched Northern Drip Extracts — their FIFTH in-house brand (joining Buzz, Happy Hour, NU, and Chomp). Extracts/concentrates are one of the fastest-growing segments in Canada and this mid-to-premium line is going straight into medical + recreational + wholesale channels. BC cannabis market is on fire (Q1 sales strong + 677% YoY direct delivery growth) and Herbal Dispatch is perfectly positioned with their upgraded e-comm platforms and expanding SKUs. Their 2026 plan called for 40%+ YoY recreational growth and 15%+ BC market share — with the house-of-brands strategy and new extracts drop, they're over-delivering.

This isn't some random weed stock hoping for legalization — $HERB already has the platforms, the brands, the insurance relationships, the export lanes, and the execution. Revenue run-rate accelerating, margins expanding, multiple growth levers firing at once. Low float, OTCQB + DTC eligible, and still flying under the radar.

Positioned for a monster 2026. CSE: $HERB OTCQB: $LUFFF

Just in from today (May 5, 2026): Herbal Dispatch ($HERB / $LUFFF / $HA9) launched their upgraded HeroDispatch.com platform alongside major enhancements to HerbalDispatch.com. This is their next-generation Shopify-based e-commerce setup built specifically for veterans, insured medical patients, and clinics.

They’re laser-focused on Canada’s $245 million insured medical cannabis segment (driven by Veterans Affairs Canada reimbursements), which is massively underpenetrated. There are over 600,000 veterans in Canada, chronic pain is a top disability, and medical cannabis is a go-to treatment — yet only ~30,000 vets are currently using the reimbursement program. That’s a huge runway. Veterans clients could be one of the most important parts of this business:

• Dedicated HeroDispatch.com platform with seamless insurance billing, clinic integration, concierge support, and curated products.
• Gross margins exceeding 50% in the veteran channel — insane unit economics.
• Extremely high retention and recurring purchases (patients come back month after month).
• Resilient demand even with recent policy tweaks — insured = reliable revenue.

CEO Philip Campbell knows this is a under utilized market:

“This channel is highly efficient, with strong margins and recurring revenue that support long term scalability and predictable growth.”

High retention + 50%+ margins + recurring insured sales = scalable, predictable cash flow that can drive serious revenue growth and EBITDA expansion. With the new platform removing friction for clinics and patients, $HERB is positioned to capture a big chunk of this under served market and turn it into serious shareholder value. This comes right after their strong Q4 (positive adjusted EBITDA, $6.2M gross sales) and international export wins ($350k first of many tranches to a auz on behalf of a top 3 global cannabis company). The setup is looking better than ever. GLTA

Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce the launch of the upgraded HeroDispatch.com, alongside significant enhancements to HerbalDispatch.com for standard medical patients.

These upgraded platforms are designed to position Herbal Dispatch as a preferred partner for both patients and clinic operators nationwide, delivering improvements across integration, user experience, and operational scalability.

Platform Advantages

The enhanced HeroDispatch platform streamlines clinic workflows and elevates the patient experience, creating a more efficient and scalable medical channel. Herbal Dispatch operates a portfolio of Shopify-based e-commerce platforms tailored to distinct customer segments, enabling the Company to optimize user experience, marketing, and product offerings while leveraging a shared backend infrastructure. HeroDispatch.com serves as the Company's dedicated platform for veterans and insured medical patients, supporting insurance-backed purchasing, and clinic integration to drive higher conversion, retention, and lifetime value within this segment. The veteran channel delivers strong unit economics for the Company, with gross margins exceeding 50%, reinforcing its position as a highly scalable and high-quality recurring revenue stream.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6253/295902_2976eaf0d4913b17_001full.jpg

For customers, the platform delivers a simplified and personalized experience through curated product selection, transparent pricing, concierge-style support, and seamless direct insurance billing. These features support strong patient satisfaction, high retention, and recurring revenue.

Strategic Market Opportunity

The upgraded HeroDispatch.com targets Canada's large and underpenetrated insured medical cannabis segment for veterans and fully insured patients-a market driven primarily by Veterans Affairs Canada reimbursements of approximately $245 million annually based on recent reporting, with reimbursements expected to continue to grow into 2026.

Canada currently has approximately 600,000+ veterans, with research from Statistics Canada indicating that Chronic Pain is one of the highest causes of disability or activity limitation for Veterans. Chronic pain is one of the most common conditions where medical cannabis is used, however, only approximately 30,000 veterans are currently participating in reimbursement programs, indicating significant underpenetration and a substantial opportunity to expand adoption within this segment.

Despite recent policy adjustments in Budget 2025, the Company continues to see resilient demand in this segment, which is characterized by high retention and recurring purchasing. Herbal Dispatch believes this positions HeroDispatch as a leading platform to capture share in one of the most attractive verticals in Canadian cannabis.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6253/295902_2976eaf0d4913b17_002full.jpg

The Company believes HeroDispatch is well positioned to become a leading platform for insured medical cannabis patients in Canada, supported by its integrated technology, patient-centric model, and expanding national footprint.

Future Initiatives

In parallel, Herbal Dispatch is evaluating the launch of its own medical clinic to enhance service delivery, accelerate onboarding, and capture additional value across the patient lifecycle. The Company currently incurs recurring third-party costs related to initial patient registration and annual renewals; internalizing these functions is expected to materially increase per-patient margin contribution while improving conversion, retention, and overall operating leverage.

"HeroDispatch.com represents a meaningful advancement in how we provide medical cannabis to our customers. We have focused on eliminating friction for clinics while delivering a more seamless and personalized experience for patients. The strength of our model is reflected in our retention and ongoing patient engagement, and we continue to see increasing adoption from both patients and healthcare providers," stated Philip Campbell, CEO of Herbal Dispatch. "From a business standpoint, this channel is highly efficient, with strong margins and recurring revenue that support long-term scalability and predictable growth."

Vancouver, British Columbia--(Newsfile Corp. - April 30, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), today announces the successful completion of its first export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue and marking a significant milestone in the Company's international growth strategy.

The export reflects accelerating global demand for regulated cannabis edibles and reinforces Herbal Dispatch's ability to deliver compliant, high-quality products into international markets. The customer for this shipment is a top three global cannabis company, further validating Herbal Dispatch's positioning as a trusted supply partner in the international medical cannabis ecosystem.

"We are pleased to have successfully completed the first tranche of our export of premium cannabis gummies to Australia," said Philip Campbell, CEO of Herbal Dispatch "This milestone highlights both the strength of our product offering and our ability to execute in regulated international markets. We view this as an important step in scaling a high-margin export channel and establishing recurring international revenue streams."

The shipped products consist of Herbal Dispatch's medical cannabis gummies, produced in compliance with Canadian federal regulations and applicable GMP standards. Based on current demand and partner engagement, the Company anticipates additional follow-on shipments in 2026, subject to regulatory approvals and market conditions.

The Company currently maintains active export relationships across multiple international markets, including Australia, Portugal, Germany (most recently in January 2026), Brazil, Czech Republic, United Kingdom, Switzerland, and Costa Rica, reflecting the continued expansion of its global distribution footprint.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6253/295081_herb2_550.jpg

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6253/295081_herb2.jpg

Expanding Edibles Strategy

In parallel with its international initiatives, Herbal Dispatch is actively expanding its gummies and edibles offering domestically under the Chomp brand, responding to strong and growing consumer demand across both medical and recreational channels. The Company views edibles as a key category for long-term growth, driven by consumer preference for convenient, dose-controlled formats and increasing adoption across global markets.

Herbal Dispatch's integrated platform—spanning product development, distribution, and direct-to-consumer channels—positions the Company to capture share in the expanding edibles segment both in Canada and internationally.

This initial export shipment represents a meaningful step forward in Herbal Dispatch's broader strategy to scale its international footprint while simultaneously strengthening its domestic product portfolio. The Company continues to build a diversified revenue base across high-growth categories and jurisdictions, with a focus on margin expansion and sustainable growth.

Herbal Dispatch will provide further updates as additional shipments progress.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/6253/295081_herb-1_550.jpg

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6253/295081_herb-1.jpg

Herbal Dispatch announced today that it is accelerating its U.S. market plans in response to the U.S. HHS recommendation to move cannabis from Schedule I to Schedule III. This potential reclassification, if finalized by the DEA, would remove the Section 280E tax burden, improve access to banking and institutional capital, and support broader industry growth.

Key points from the update:

• The company is evaluating strategic partnerships, joint ventures, and platform distribution opportunities in the U.S. with a focus on medical cannabis channels.
• Herbal Dispatch plans to leverage its experience in patient acquisition, veteran programs, and direct-to-consumer medical sales from its Canadian operations.
• Its asset-light, tech-enabled e-commerce model is designed for efficient scaling with lower capital requirements.
• Already listed on OTCQB (LUFFF) with recent DTC eligibility, which should help with U.S. investor access and liquidity.

The company has built a solid base in Canada through its craft cannabis e-commerce platform and continues to focus on growth there while preparing for U.S. opportunities. This looks like a measured approach to position for potential regulatory changes. Worth watching if you're following cannabis stocks. What are your thoughts on this one?

Anyone following $HERB / $LUFFF?

https://www.newsfilecorp.com/release/294309/Herbal-Dispatch-Advances-U.S.-Strategy-amid-Historic-Cannabis-Rescheduling-Shift

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), announces its financial results for the fourth quarter and year ended December 31, 2025.

Q4 2025 HIGHLIGHTS

Gross sales of $6.2 million, representing a 115% increase compared to $2.9 million in Q4 2024

Net revenue of $4.1 million (excluding excise taxes), up from $2.3 million in Q4 2024

Adjusted EBITDA of $0.1 million, compared to $(0.6) million in Q4 2024

Adjusted EBITDA of $0.2 million excluding non-recurring costs related to investor relations and financing

FY 2025 HIGHLIGHTS

Gross sales of $16.5 million, representing a 37% increase compared to $12.1 million in 2024

Net revenue of $12.1 million (excluding excise taxes), up from $9.9 million in 2024

Adjusted EBITDA of $(0.7) million, improved from $(1.0) million in 2024

Gross margin improved to approximately 22.7% in 2025, compared to 20.1% in 2024, reflecting enhanced cost of goods efficiency, improved product mix, and increasing scale across the Company's platform and the Company expects continued improvement into 2026 as scale and operating leverage continues to increase.

STRATEGIC MOMENTUM

Completed an oversubscribed non-brokered private placement, raising $2.1 million in October 2025

Commenced trading on the OTCQB® Venture Market under the ticker LUFFF subsequent to year end

FINANCIAL PERFORMANCE

For the three months ended December 31, 2025, gross sales increased by 115% to $6.2 million compared to $2.9 million in Q4 2024. Net revenue, excluding excise taxes, increased to $4.1 million compared to $2.3 million in the prior year quarter. The increase was driven by higher sales volumes across both medical and recreational channels and continued growth within the Company's e-commerce platform.

As of this period, the Company's path to profitability is increasingly driven by expanding gross margins, with gross profit growing to $2.75 million in 2025 from $2.0 million in 2024, reflecting improved cost of goods sold efficiency and increasing operating leverage across the platform.

Gross profit improved in Q4 2025 as a result of increased scale and improving operating efficiencies. Cost of goods sold as a percentage of sales declined year-over-year, reflecting enhanced purchasing power, optimized product mix, and improved supply chain execution. This expansion in gross margin is a key driver of the Company's path to sustained profitability and operating leverage.

Adjusted EBITDA improved significantly in Q4 2025 to positive $0.1 million, compared to negative $0.6 million in Q4 2024, driven primarily by increased scale and improved gross margins. Excluding certain non-recurring investor relations costs and professional fees related to the October 2025 private placement, adjusted EBITDA for Q4 2025 would have been positive $0.2 million.

For the full year ended December 31, 2025, adjusted EBITDA improved by 30% to negative $0.7 million compared to negative $1.0 million in 2024, reflecting continued progress toward profitability.

MANAGEMENT COMMENTARY

"The fourth quarter of 2025 marked a major step forward for Herbal Dispatch, as we delivered record quarterly gross sales and achieved positive adjusted EBITDA," said Philip Campbell, President & CEO of Herbal Dispatch. "We have now achieved double-digit growth for the third consecutive year, reflecting the strength of our platform, our customer relationships, and our ability to expand across both Canadian and international markets."

"Looking ahead to 2026, our focus remains on scaling profitably, expanding our recreational footprint, growing medical sales-particularly among veterans-and accelerating export growth into federally legal international markets. With strong sales momentum and the added visibility of our OTCQB listing, we believe we are well-positioned to create long-term value for shareholders."

CONSOLIDATED FINANCIAL STATEMENTS

The Company's consolidated financial statements and management's discussion & analysis for the year ended December 31, 2025 are available on the Company's profile on SEDAR+ at www.sedarplus.ca and will also be posted on the Company's website at www.herbaldispatch.com.

ABOUT HERBAL DISPATCH INC.

Herbal Dispatch Inc. is a leading operator of cannabis e-commerce platforms in Canada, delivering quality medical and recreational products to discerning consumers at competitive prices. Its flagship marketplace has earned trust as a premier destination for exclusive access to small-batch craft cannabis and a wide selection of curated cannabis products. The Company is also actively expanding through exports to international markets, positioning it for sustained growth and new revenue opportunities. The Company's common shares trade on the Canadian Securities Exchange under the symbol "HERB".

For further information: Philip Campbell, CEO and Director Email: IR@herbaldispatch.com Telephone: 1-833-432-2420

NON-IFRS MEASURES

Adjusted EBITDA is defined as earnings before interest, income taxes, depreciation, amortization, share based compensation, loss (gain) on disposal of assets, loss (gain) on investments, loss (gain) on extinguishment of debt, impairment losses, loss (gain) on foreign exchange and accretion expense. The Company believes that, in addition to net income (loss), adjusted EBITDA is a useful measure as it provides an indication of the financial results generated by its principal business activities prior to consideration of how these activities are financed or how the results are taxed in various jurisdictions and before certain non-cash items such as depreciation, amortization, and other items. Adjusted EBITDA does not have any standardized meaning as prescribed by IFRS and therefore, is considered a non-IFRS measure and may not be comparable to similar measures presented by other issuers.

A reconciliation of net loss to adjusted EBITDA for each of the periods presented in this news release follows:

https://api.newsfilecorp.com/redirect/vEYvOIoRm1

$HERB.CN / OTC: $LUFFF